Key result
This review summarizes the structure, function, mechanism of action, and research progress of influenza virus polymerase acidic protein endonuclease inhibitors.
Why the study?
Increasing resistance to existing influenza drugs drives the search for novel antivirals with new mechanisms, such as inhibiting polymerase acidic protein endonuclease activity.
This review summarizes the mechanism and research progress of influenza virus polymerase acidic protein endonuclease inhibitors, a novel class of antiviral drugs.
May guide antiviral development; leaves open clinical adoption pending trials.
Influenza is a type of acute respiratory virus infection caused by the influenza virus that occurs in epidemics worldwide every year. Due to the increasing incidence of influenza virus resistance to existing drugs, researchers are looking for novel antiviral drugs with new mechanisms. The endonuclease activity of polymerase acidic protein is essential in the process of influenza virus reproduction, and inhibiting it could prevent the virus from replicating. There are relatively few drugs that act on this protein, and only baloxavir marboxil has been approved for clinical use. In this article, the structure and function of influenza virus polymerase acidic protein endonuclease, mechanism of action of polymerase acidic endonuclease inhibitors and the research progress of inhibitors are reviewed.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2022) conducted a review in Influenza. Polymerase acidic endonuclease inhibitors was evaluated. This review summarizes the structure, function, mechanism of action, and research progress of influenza virus polymerase acidic protein endonuclease inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: